Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY

INTEGRA LIFESCIENCES HOLDINGS CORP

2025-Q2 EPS reported -$6.65 revenue$798,258,000

Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
GAAP net loss $484.1M includes $511M goodwill impairment; adjusted EBITDA $71.2M (17.1% margin) vs $83.8M (20.0%) prior year.
Full-year 2025 revenue guidance narrowed to $1.655B–$1.680B; adj EPS reaffirmed at $2.19–$2.29.
Net debt $1.59B; total leverage ratio 4.5x; liquidity ~$1.14B including $254M cash and short-term investments.
Completed all manufacturing site baseline assessments under Compliance Master Plan; no new shipping holds in Q2.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.